Vanguard Group Inc. Increases Position in Azenta, Inc. $AZTA

Posted by Geri Gentry on May 12th, 2026

Vanguard Group Inc. raised its holdings in shares of Azenta, Inc. (NASDAQ:AZTA – Free Report) by 2.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,538,946 shares of the company’s stock after buying an additional 99,588 shares during the period. Vanguard Group Inc. owned about 9.87% of Azenta worth $150,965,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Assetmark Inc. boosted its position in shares of Azenta by 54.1% during the fourth quarter. Assetmark Inc. now owns 832 shares of the company’s stock valued at $28,000 after buying an additional 292 shares during the period. Osaic Holdings Inc. boosted its position in shares of Azenta by 44.9% during the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock valued at $39,000 after buying an additional 385 shares during the period. CWM LLC boosted its position in shares of Azenta by 27.3% during the fourth quarter. CWM LLC now owns 1,822 shares of the company’s stock valued at $61,000 after buying an additional 391 shares during the period. Neuberger Berman Group LLC boosted its position in shares of Azenta by 6.2% during the third quarter. Neuberger Berman Group LLC now owns 7,695 shares of the company’s stock valued at $221,000 after buying an additional 451 shares during the period. Finally, Empowered Funds LLC boosted its position in shares of Azenta by 10.5% during the first quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock valued at $225,000 after buying an additional 618 shares during the period. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Azenta Stock Down 6.6%

Azenta stock opened at $17.95 on Tuesday. The business has a fifty day moving average of $22.81 and a two-hundred day moving average of $29.87. The firm has a market cap of $826.78 million, a P/E ratio of -4.53 and a beta of 1.43. Azenta, Inc. has a twelve month low of $17.11 and a twelve month high of $41.73.

Azenta (NASDAQ:AZTA – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The company had revenue of $144.80 million for the quarter, compared to analysts’ expectations of $148.47 million. Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.01 EPS.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on AZTA shares. Jefferies Financial Group lowered their price target on Azenta from $42.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Weiss Ratings downgraded Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Evercore lowered their target price on Azenta from $50.00 to $45.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Zacks Research upgraded Azenta from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Finally, TD Cowen reiterated a “hold” rating on shares of Azenta in a report on Wednesday, February 4th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $39.50.

Read Our Latest Stock Analysis on Azenta

Azenta Profile

(Free Report)

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.

Vanguard Group Inc. Increases Position in Azenta, Inc. $AZTA

Azenta Stock Down 6.6%

Analyst Upgrades and Downgrades

Azenta Profile

Recommended Stories

You might be interested in: